Navigation Links
Controversial theory of Alzheimer's origin funded
Date:1/25/2008

MELBOURNE, FLA. Dr. Shaohua Xu, Florida Tech associate professor of biological sciences, has an original theory of the origin of Alzheimers Disease and has earned a $150,000 grant from Space Florida to test it. The grant was matched with $30,000 from NASAs Aerospace Medicine and Occupational Health Branch.

He is also the sole medical researcher at the State of Floridas Space Life Sciences Laboratory at Kennedy Space Center (KSC) and the research is being conducted both at the university and KSC.

Xus theory, both controversial and praised, involves the start of the disease when molecules of a normal brain cell protein called tau do something very abnormal: they join together to form tangled fibers that the cell cannot remove. The fibers accumulate until essential substances cannot move through the cell and the cell dies, creating onset of the disease.

Using atomic force microscopy, Xu has studied for the first time the actual process by which the fibers form. Xu uses purified proteins to synthesize the fibers into their various forms.

We find that it is a three-step process, he says. First, molecules of the tau protein cluster together into spheres, each almost the same size. Next, the spheres join together in linear chains like beads on a string. In the third stage the beads merge together to form a uniform filament identical to those found in the brains of patients with the disease.

Advocates of Xus theory are numerous. Daniel Woodard, KSC physician, was the first medical doctor to review the research. He says, Shaohuas theory is revolutionary; his evidence is overwhelming. The medical implications are beyond anything in my experience.

NASA physician David Tipton, chief of the Aerospace Medicine and Environmental Health Branch at KSC, says, This could be the most important biomedical discovery ever made at Kennedy Space Center.

Additionally, Pamela Tronetti, medical director of the Parrish Senior Consultative Center, predicts, If this theory is correct, it may very well have as great an impact on neurodegenerative disease as the discovery of germs had on infection.

The more common theory of Alzheimers origin is that the filaments form by the addition of individual tau molecules to the tip of the fiber.

From our own observations, we believe this theory is incorrect, says Xu. The process we have observed closely resembles that of colloid formation, mixtures like milk or ink in which tiny particles are suspended in a fluid. Our theory is based on colloid science.

Xu affirms that if his theory is correct, it may be possible to halt the disease with drugs that hinder the aggregation of the spherical colloidal particles into linear chains. Similar chemicals are already used to stabilize colloidal materials such as paints.

Xu began developing this theory in 1997, when he conducted Mad Cow Disease research at the University of Chicago. The research continues to have applications for Mad Cow Disease as well as Parkinsons Disease, both of which appear to have very similar mechanisms. Xu will be testing potential drugs that may be able to halt the formation of the filaments.


'/>"/>

Contact: Karen Rhine
krhine@fit.edu
321-698-3279
Florida Institute of Technology
Source:Eurekalert

Related medicine news :

1. Controversial Anemia Drug Doesnt Cut Need for Transfusions
2. Controversial physical agents directive postponed
3. Study Supports Controversial Heart Failure Drug
4. Controversial New Report Details Successes and Challenges as the Microcredit Movement Escalates Its Battle With Poverty
5. Study Puts 1 Alzheimers Theory in Doubt
6. Discovery supports theory of Alzheimers disease as form of diabetes
7. Carnegie Mellon neuroscientist proposes new theory of brain flexibility
8. Research may unlock mystery of autisms origin in the brain
9. Susan G. Komen for the Cure Partners With the Original Butter Bell(R) Crock Developer
10. Worm Study Points to Sexualitys Origins
11. Studies Investigate Diagnostic Performance and Reproducibility of Pathwork Diagnostics Tissue of Origin Test
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... ... Brent Kasmer, a legally blind and certified personal trainer is helping to develop a weight ... app plans to fix the two major problems leading the fitness industry today:, ... program , They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... Washington, D.C. (PRWEB) , ... June 25, 2016 ... ... will discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June ... share their work on several important health care topics including advance care planning, ...
(Date:6/25/2016)... ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due ... up a new, often overlooked aspect of head lice: the parasite’s ability to live away ... a common occurrence, but a necessary one in the event that lice have simply gotten ...
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding emergency ... its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. Ogunleye ... M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. Ogunleye ...
(Date:6/25/2016)... Oklahoma City, Oklahoma (PRWEB) , ... June 25, ... ... to helping both athletes and non-athletes recover from injury. Recently, he has implemented ... for the Oklahoma City area —Johnson is one of the first doctors to ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
(Date:6/23/2016)... LOS ANGELES , June 23, 2016 /PRNewswire/ ... (NASDAQ: CAPR ), a biotechnology company ... first-in-class therapeutics, today announced that patient enrollment in ... progrEssion in Duchenne) has exceeded 50% of its ... its enrollment in the third quarter of 2016, ...
Breaking Medicine Technology: